Propionic Acid May Help Protect Nerves in MS - New Hope

Credibility

Interest

Share:2 min read

Key Takeaway

Adding propionic acid supplements for 90 days lowered a blood marker of nerve damage in people with stable MS and was well tolerated.

What They Found

Researchers gave 101 adults with stable MS either propionic acid (PA) or a placebo for 90 days and then checked results. They measured a blood marker called serum neurofilament light chain (sNfL), which rises when nerve fibers are being damaged; people taking PA had a clear drop in sNfL levels. The PA group showed about an 18% drop in this blood marker, while the placebo group did not change in a meaningful way. The drop happened even in people already on strong MS medicines, including those on anti-CD20 drugs, suggesting PA added benefit on top of usual treatments. No serious side effects from PA were reported, and people tolerated the supplement well, with a small sign of less motor fatigue (feeling physically tired when moving).

Who Should Care and Why

People with MS and their caregivers should notice that this study suggests a simple supplement might help reduce ongoing nerve injury, like adding a small shield to protect nerves. Clinicians and caregivers might consider this as a possible add-on to current MS treatments, similar to putting on a raincoat in addition to carrying an umbrella—extra protection, not a replacement. Those on strong disease-modifying therapies, including anti-CD20 drugs, may especially pay attention because the benefit appeared even when these drugs were used. If you worry about nerve damage over time (which can show up as increased fatigue, trouble walking, or thinking problems), this finding is relevant because the study used a blood test that tracks that damage. However, this was a short, single-centre trial, so patients should discuss with their MS care team before starting any new supplement.

Important Considerations

This was a small, 90-day study at one center, so we don’t know if benefits last long-term or work the same for everyone. The main result relies on a blood marker (sNfL) that predicts nerve damage, but the study did not prove clear improvements in daily function or long-term disability yet. These results are promising but need larger, longer trials before PA can be recommended for routine use.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials Nutrition

Article Topics:

add-on therapyclinical trialmultiple sclerosisneurofilament light chainneuroprotectionpropionic acid

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Brain : a journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News